This is the third step along the Road To Collaboration in clinical trials. My second article ended on the realisation that significant remission of symptoms exacts an unexpected toll on a participant.The memory of function temporarily restored is now being aggravated. The Foliglurax Trial is reportedly slipping, so disclosure of drug/placebo remains a distant prospect. To the lack of […]
Author: Chris Maycock
PD Research Expenditure – It’s Complicated
To investigate expenditure on PD research as a platform for advocacy is to sink immediately into a sea of complications. The US is possibly the most transparent jurisdiction in the world on medical spending, so let’s start with US spending on PD research. In 2017 it was $177m, with a reduction to $169m in prospect […]
The Road To Collaboration 2 – Clinical Trials
Sponsors of clinical trials need participants, but people do not need to participate. They may want to, but they do not have to. Want implies freedom of action and an expectation of persuasion. The difference between want and need tells us who ultimately should be in charge of thiis arrangement. A Clinical Trial Team is an agent […]